Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.32
RTRX's Cash to Debt is ranked higher than
56% of the 926 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. RTRX: 0.32 )
RTRX' s 10-Year Cash to Debt Range
Min: 0.13   Max: No Debt
Current: 0.32

Equity to Asset -0.07
RTRX's Equity to Asset is ranked lower than
54% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. RTRX: -0.07 )
RTRX' s 10-Year Equity to Asset Range
Min: -3.16   Max: 0.01
Current: -0.07

-3.16
0.01
F-Score: 3
Z-Score: -2.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 905.77
RTRX's Operating margin (%) is ranked higher than
100% of the 875 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.10 vs. RTRX: 905.77 )
RTRX' s 10-Year Operating margin (%) Range
Min: 345.21   Max: 345.21
Current: 905.77

Net-margin (%) 883.56
RTRX's Net-margin (%) is ranked higher than
100% of the 875 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.05 vs. RTRX: 883.56 )
RTRX' s 10-Year Net-margin (%) Range
Min: 345.99   Max: 345.99
Current: 883.56

ROA (%) -108.41
RTRX's ROA (%) is ranked lower than
53% of the 930 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.82 vs. RTRX: -108.41 )
RTRX' s 10-Year ROA (%) Range
Min: -375   Max: -329.94
Current: -108.41

-375
-329.94
ROC (Joel Greenblatt) (%) -30590.31
RTRX's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 925 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.02 vs. RTRX: -30590.31 )
RTRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -53146.46   Max: -53146.46
Current: -30590.31

EPS Growth (3Y)(%) 209.70
RTRX's EPS Growth (3Y)(%) is ranked higher than
99% of the 667 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.10 vs. RTRX: 209.70 )
RTRX' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 235.3
Current: 209.7

0
235.3
» RTRX's 10-Y Financials

Financials


Revenue & Net Income
Equity & Asset
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

RTRX Guru Trades in

RTRX Guru Trades in

RTRX Guru Trades in

Q1 2014

RTRX Guru Trades in Q1 2014

Steven Cohen 3,932 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with RTRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Retrophin Inc

Largest Insider Buys of the Week
Over the past week there were several companies reporting smaller insider buys along some large insider sells. The following insiders reported the largest insider buys over the past week. These transactions were judged based on the number of insiders buying, transaction amount and the amount of shares being purchased Read more...
Weekly CEO Buys Highlight: OPK, RTRX, TFM, CSBK, AHP
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Three CEOs Reporting Large Insider Buys
Over the past week we’ve seen several large insider buys as well as several coming from the companies’ CEOs. It is interesting to note when a CEO, or even a CFO, buys because these insiders supposedly have the most intimate knowledge of their company's workings. Read more...

Ratios

vs
industry
vs
history
EV-to-EBIT -4.13
RTRX's EV-to-EBIT is ranked higher than
58% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.09 vs. RTRX: -4.13 )
RTRX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -4.13

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -24.20
RTRX's Earnings Yield (Greenblatt) is ranked lower than
51% of the 927 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. RTRX: -24.20 )
RTRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -36.5   Max: 0
Current: -24.2

-36.5
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:17R.Germany,
Retrophin, Inc., was incorporated as Desert Gateway, Inc. as an Oklahoma corporation on February 8, 2008. On February 14, 2013, the Company changed its name to Retrophin, Inc. The Company is a fully integrated biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It is developing Syntocinon Nasal Spray in the U.S. to assist initial postpartum milk ejection, which it refers to as aiding milk let-down, and for the treatment of Schizophrenia and Autism. It is also developing RE-034, a synthetic hormone analogue that is composed of the first 24 amino acids of the 39 amino acids contained in the naturally occurring adrenocorticotrophic hormone, or ACTH, for the treatment of Infantile Spasms, or IS, and Nephrotic Syndrome, or NS. It is developing sparsentan, formerly known as RE-021, a dual acting receptor antagonist of angiotensin and endothelin receptors, for the treatment of focal segmental glomerulosclerosis, or FSGS. The Company competes with Genentech, GlaxoSmithKline, Roche, Novartis, Pfizer, Boehringer Ingelheim, Sanofi, BioMarin, Sarepta, Vertex, and Jazz Pharmaceuticals. The Company is subject to federal, state and local laws governing the use, handling and disposal of these materials.
» More Articles for RTRX

Headlines

Articles On GuruFocus.com
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Retrophin, Inc. Nov 28 2014 
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Retrophin, Inc. Oct 24 2014 
Largest Insider Buys of the Week Apr 07 2014 
Weekly CEO Buys Highlight: OPK, RTRX, TFM, CSBK, AHP Apr 07 2014 
Three CEOs Reporting Large Insider Buys Apr 04 2014 
Steven Cohen Tops GuruFocus' Real Time Picks of the Week Apr 04 2014 
Morning Coffee: See Which Insiders are Buying Apr 04 2014 
Weekly CEO Buys Highlight: CLMS, OPK, OVAS, RTRX, MDCA Mar 17 2014 
Weekly CEO Buys Highlight: KMI, CLMS, RTRX, OPK, KO Mar 03 2014 
Weekly CEO Buys Highlight: RSE, RHP, RTRX, CLMS Jan 21 2014 

More From Other Websites
RETROPHIN, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Mar 04 2015
Tim Coughlin Joins Retrophin's Board of Directors Mar 04 2015
Tim Coughlin Joins Retrophin’s Board of Directors Mar 04 2015
RETROPHIN, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing... Mar 03 2015
Gadfly Pharma Investor Shkreli Starts Anew After Ousting From Retrophin Feb 27 2015
Launch of Turing Pharmaceuticals Announced - New Drug Company to Focus on Treating Unmet Medical... Feb 24 2015
Biotech's 'Boy Genius' Faces New Allegations of Wrongdoing Feb 23 2015
RETROPHIN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Non-Reliance on... Feb 20 2015
Retrophin to Report Fourth Quarter and Full Year 2014 Financial Results Feb 20 2015
Retrophin to Report Fourth Quarter and Full Year 2014 Financial Results Feb 19 2015
RETROPHIN, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Feb 13 2015
RETROPHIN, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to... Feb 09 2015
Retrophin to Present at the 2015 Leerink Global Healthcare Conference Feb 05 2015
Retrophin to Present at the 2015 Leerink Global Healthcare Conference Feb 05 2015
Retrophin Announces Voting Results of Special Meeting of Stockholders Feb 03 2015
Retrophin Definitive Proxy Filing - January 23, 2015 Jan 23 2015
RETROPHIN, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of... Jan 13 2015
Retrophin Announces Acquisition of Exclusive Right to Purchase Cholic Acid from Asklepion... Jan 12 2015
Retrophin Announces Acquisition of Exclusive Right to Purchase Cholic Acid from Asklepion... Jan 12 2015
The Shuman Law Firm Investigates Retrophin, Inc. Jan 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK